MedPath

Ventilator Aspiration With PneuX (PneuX vs Standard Care Feasibility RCT)

Not Applicable
Recruiting
Conditions
Infections
Aspiration
Ventilator Associated Pneumonia
Ventilator Lung
Interventions
Device: PneuX Endotracheal Tube
Device: Standard care (Taperguard, Covidien)
Registration Number
NCT05410106
Lead Sponsor
Cardiff and Vale University Health Board
Brief Summary

This is a single centre, open-label, feasibility randomised controlled trial. The study aims to assess the feasibility of conducting an RCT to compare the PneuX ETT with standard care in hospitalised patients requiring mechanical ventilation. The patient population for this study are those who are experiencing critical illness requiring intubation and ventilatory support. Patients will be randomised in equal proportions into one of 2 arms: to be intubated using a Venner PneuX Endotracheal Tube (ETT) or using the standard tube. For this feasibility study, a total of 50 patients will be randomised into two groups (25 in each). All patients will be recruited at a single site (University Hospital of Wales, part of Cardiff \& Vale UHB). The study will investigate several feasibility measures including recruitment, delivery of the intervention (including device-related adverse events), acceptability and adherence to the intervention and sampling, use of Peptest to measure microaspiration events, rate of pepsin positive samples, rate of tracheobronchial colonisation, volume of sub-glottic aspirate, rate of VAP, length of ICU and hospital stay, demonstrate the validity of study documentation and provide preliminary data for 50 patients. The data will inform the pilot and main phase of the study.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
50
Inclusion Criteria
  • 18 years old (no upper age)
  • Patient required endotracheal intubation
  • Expect to remain intubated for 24 hours post randomisation
Exclusion Criteria
  • The person intubating the patient assesses that the patient has already aspirated.
  • GCS 7 or less on presentation to hospital
  • Patient is pregnant
  • Patient has tracheostomy
  • Patient has gastrectomy
  • Patients who have been intubated prior to arrival at hospital
  • Patients who are already endotracheally intubated and require a tube change.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
PneuX endotracheal tubePneuX Endotracheal TubePatients will be intubated using the PneuX endotracheal tube system
Standard careStandard care (Taperguard, Covidien)Patients will be intubated using standard endotracheal tube (Taperguard, Covidien).
Primary Outcome Measures
NameTimeMethod
To assess if a recruitment rate of 50 patient annually is achievable and identify any barriers to recruitmentThrough study completion, an average of 1 year

The recruitment rate will be assessed using the "screening and recruitment log" which will record the number of patients recruited each month and reasons for non-recruitment will be described

Secondary Outcome Measures
NameTimeMethod
Number of participants with a failed pepsin testDuration of study treatment (typically 4-7 days)

Any issues such as failed sampling or failed testing will be recorded in case report form

Proportion of patients who require antibiotics28 days

The following will be assessed: antibiotic prescribed, indication for use, number of days administered

Rate of Ventilator Associated Pneumonia (VAP)28 days

Number of patients with VAP diagnosis. Clinical Pulmonary Infection Score (CPIS) used to predict VAP. CPIS \>6 will be used to define confirmation of VAP. Measured daily after 48 hours of intubation

Number of participants with a positive pepsin tracheal aspirate sample using PeptestDuration of study treatment (typically 4-7 days)

The proportion of tracheal aspirate samples which are positive for the presence of pepsin using the Peptest test

Time spent on the ventilatorDuration of study treatment (typically 4-7 days)

Days spent with mechanical ventilation in ICU (from time/date of intubation to time/date of extubation or 28 days)

Number of days spent in ICU and hospital28 days

Length of stay in ICU and length of stay in hospital measured in days from ventilation

Rate of in-hospital mortality28 days

Number of patients who die in hospital up to 28 days after entry into ICU

Volume of sub-glottic aspiratesDuration of study treatment (typically 4-7 days)

The volume of the sub-glottic aspirates will be measured every 24 hours

To assess the feasibility of delivering the study interventionDuration of study treatment (typically 4-7 days)

Any issues experienced when using the study device at any point during the study will be recorded in the CRF, including device-related complications.

Rate of tracheobronchial colonizationDuration of study treatment (typically 4-7 days)

Tracheobronchial colonization (no. colony forming units/ml) present in sputum samples will be measured by culture on days 3 and 7

Rate of compliance with measuring and documenting cuff pressureDuration of study treatment (typically 4-7 days)

Documentation of cuff pressures in both arms of study. Cuff pressure in standard care will be measured every 12 hours. Assessment of intervention arm will have documentation that pressure has been maintained hourly either via the continual cuff pressure monitor or manually.

Trial Locations

Locations (1)

University Hospital of Wales

🇬🇧

Cardiff, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath